不同方式构建A20鼠B细胞淋巴瘤动物模型

目的探索多种方式构建A20鼠B细胞淋巴瘤动物模型及不同方式造模成瘤的特征。方法鼠源性B细胞淋巴瘤细胞株A20经皮下、尾静脉、脾脏和腹腔接种于同源BALB/c小鼠或先接种裸鼠成瘤后组织块移植BALB/c小鼠,观察动物成瘤时间、成瘤率、成瘤部位;取肿瘤组织和动物脏器行石蜡包埋、病理切片、HE染色观察其组织学特点。结果BALB/c鼠皮下注2×10^6组、2×10^7组和裸鼠瘤组织移植BALB/c小鼠组成瘤率皆为100%,成瘤时间分别为（15.29±3.2）d（、7.0±0.82）d和（6.29±0.49）d。BALB/c小鼠尾静脉注射2×106组、2×107组、脾脏注射组、腹腔注射组成瘤率分别为71.4%、100%、71.4%、14.3%,成瘤时间分别为（76.8±12.0）d、（26.1±7.99）d、（32.6±5.99）d和27 d。尾静脉成瘤部位播及肝脏、脾脏、胰腺、肾脏、食道、胃、肠、肠系膜、脑、淋巴结、骨、子宫、肌肉等多脏器和组织。BALB/c鼠A20成瘤组织学类似人弥漫大B细胞淋巴瘤。结论成功构建A20皮下移植瘤模型、血行播散性模型,为利用有免疫功能动物进行B淋巴瘤相关研究提供了实验平台。     

三株荧光素酶标记的小鼠乳腺癌细胞在小鼠体内生长及转移的比较

目的采用活体成像技术比较三株荧光素酶标记的小鼠乳腺癌细胞在小鼠体内生长及转移情况,为研究肿瘤转移提供理想的动物模型以及活体分析方法。方法以荧光素酶（luciferase,Luc）作为报告基因导入小鼠乳腺癌细胞4T1、66c14和4TO7中,经G418筛选获得稳定表达荧光素酶的细胞克隆并扩大培养。标记细胞稀释成1×107cells/mL,取0.1 mL进行乳腺原位及尾静脉接种BALB/c小鼠,制作小鼠乳腺原位和尾静脉移植瘤模型,比较三株细胞在小鼠体内生长及转移情况。结果获得稳定表达荧光素酶基因的细胞克隆,将Luc标记的4T1、66c14、4TO7细胞对BALB/c小鼠乳腺原位接种后7 d,均有肿瘤生长,接种后28 d,4T1细胞乳腺原位移植瘤最大,66c14细胞瘤体次之,4TO7细胞瘤体最小;接种后35 d,三株细胞乳腺原位移植瘤大小较一致,但4T1和66c14原位移植瘤均发生转移,其中4T1细胞较66c14细胞转移严重,而4TO7细胞未见转移;接种后42 d,三株细胞乳腺原位移植瘤大小无明显差别,而4T1和66c14细胞随天数的增加,移植瘤转移程度逐渐严重,4T1较66c14细胞转移更严重,呈广泛性转移,4TO7细胞仍未见转移。将Luc标记的4T1、66c14、4TO7细胞对BALB/c小鼠尾静脉接种后7 d,小动物活体成像发现小鼠肺部均能检测到荧光,其中4T1细胞接种的小鼠肺部荧光信号最强,且小鼠陆续死亡;4TO7细胞接种小鼠肺部荧光信号次之;66c14细胞接种小鼠肺部荧光信号最弱。尾静脉接种后14 d,4TO7和66c14细胞随着观察天数的增加,转移程度逐渐严重,4TO7细胞接种小鼠肺部荧光信号较66c14细胞强且小鼠陆续死亡。结论乳腺原位自发转移模型较尾静脉转移模型更真实反应了肿瘤细胞在体的转移特性,且能完整地呈现肿瘤转移的全过程,可作为研究肿瘤转移的最理想模型。     

人T细胞急性淋巴细胞白血病小鼠动物模型的建立

目的:通过建立一理想的动物模型来模拟T细胞急性淋巴细胞白血病的发病状态,为探索急性淋巴细胞白血病全新的治疗方法提供平台。方法:采用抗鼠-CD122抗体注射NOD/SCID小鼠进行预处理,通过尾静脉注射9例不同病例的白血病细胞,以及1株T-ALL细胞系。通过检测小鼠体内白血病细胞及脏器白血病细胞浸润情况,观察白血病细胞植入。将白血病细胞进行二次移植,观察移植稳定性。对白血病动物模型进行药物处理,观察小鼠生存期,模拟人体治疗反应。结果:有4例病例的细胞及T-ALL细胞株成功植入。流式细胞检测显示受体小鼠体内较多比例人CD45+细胞表达,免疫组化显示CD45+细胞浸润小鼠不同脏器,系列移植也获得成功。体内药物处理显示地塞米松能延长小鼠的生存期,与临床观察相一致。结论:成功建立经抗鼠CD122单抗预处理的人T细胞急性淋巴细胞白血病NOD/SCID小鼠模型,具有原发疾病的所有主要特征。     

EGFP-Luc-Hepa1-6细胞系的构建及其在小鼠肝癌模型中的应用

目的:构建带有增强型绿色荧光蛋白EGFP及荧光素酶luciferase的真核表达载体p CMVLuciferase-IRES2-EGFP,对肝癌细胞系Hepa1-6转染后进行稳定筛选,并将表达该载体的细胞系应用于小鼠原位肝癌模型构建,以对小鼠肝癌细胞进行稳定标记与活体示踪。方法:对p GL3-Basic质粒进行Xba I酶切、Klenow片段补平黏端、Xho I酶切获得luciferase小片段,与Xho I/Sma I酶切p IRES2-EGFP质粒获得的载体大片段连接,获得重组质粒p CMV-Luciferase-IRES2-EGFP。酶切鉴定、测序比对确认序列完全正确后,以重组载体转染Hepa1-6细胞进行稳定筛选,以荧光显微镜观察EGFP表达,报告基因实验与LuminaⅡ成像系统检测荧光素酶活性。确认该细胞系中的质粒得到表达后,以该细胞系进行C57BL/6小鼠肝脏原位接种构建肝癌模型,以LuminaⅡ成像系统连续活体监测肝癌的生长,取离体的肝癌组织制备石蜡切片(HE染色)和冰冻切片(免疫荧光染色)分别观察离体肿瘤组织病理学特征及其中肝癌细胞绿色荧光蛋白表达情况。结果:成功构建表达p CMV-Luciferase-IRES2-EGFP载体的Hepa1-6细胞系(EGFP-Luc-Hepa1-6),并以该细胞系成功构建C57BL/6小鼠原位肝癌模型,实现小鼠肝癌细胞的活体示踪与体外标记。结论:成功构建EGFP-Luc-Hepa1-6细胞系,且以此细胞系构建的小鼠原位肝癌模型可以同时实现小鼠肝癌生长的连续活体监测与离体组织检测。     

H9c2细胞对B组柯萨奇病毒3型重组株的易感性

H9c2细胞是来源于大鼠胚胎心脏组织的成肌细胞系,B组柯萨奇病毒(group B Coxsackievirus,CVB)是心肌炎和扩张型心肌病的主要病原.本研究观察了CVB3在H9c2细胞中的感染性,探讨H9c2细胞是否可用于CVB致心肌疾病的实验研究.用整合了增强型绿色荧光蛋白(EGFP)或海肾荧光素酶(RLuc)的...     

昆明小鼠和DBA/2小鼠尾静脉注射L1210细胞的比较研究

目的:通过尾静脉注射L1210细胞建立昆明小鼠及DBA/2小鼠的白血病模型,观察肿瘤细胞的迁移情况以及小鼠存活时间,为后续L1210细胞迁移的细胞内信号通路研究及抗肿瘤药物筛选奠定基础。方法:常规培养小鼠白血病细胞L1210系,将昆明小鼠及DBA/2小鼠随机分为对照组(A、C)和实验组(B、D),实验组尾静脉注射5×10^6L1210细胞,对照组注射等体积的PBS。昆明小鼠组饲养56d,DBA/2小鼠组饲养14d。定期测量小鼠体重并观察小鼠形态,取濒死小鼠以及最后解剖的小鼠的心、肝、脾、肺等脏器称重并测量,统计结果。结果:A、B、C、D组小鼠的平均存活天数分别为56、56、13.83±0.37、10.33±3.40d。昆明小鼠实验组脾脏明显肿大,肺脏有少量白细胞浸润,心脏和肝脏无明显变化,无死亡现象;DBA/2小鼠注射L1210细胞后第7d开始出现死亡,随着饲养时间的延长,死亡率不断上升。结论:昆明小鼠或DBA/2小鼠尾静脉注射L1210细胞均可引起肿瘤细胞的体内浸润。昆明小鼠尾静脉注射L1210细胞存活时间长,适合长期观察或周期比较长的实验;DBA/2小鼠尾静脉注射L1210细胞存活时间短,但实验现象明显。后期研究可以针对不同的研究目的和实验周期来选择合适的实验模型。     

新型真核表达质粒pcDNA6/myc-his-EGFP B 的构建及其在重组基因表达中的应用

增强型绿色荧光蛋白（EGFP, enhanced green fluorescent protein）、myc抗原和6×His已在众多真核表达载体中用作重组蛋白的表达标记,EGFP能发出的绿色荧光,myc抗原能用相应的抗体检测,6×His能被相应的树脂特异吸附。但目前为止,没有一个质粒表达载体能够同时整合三者的功能。本研究构建了一个能够同时整合EGFP、myc抗原和6×His功能的新型真核质粒表达载体,我们将其命名为pcDNA6/myc-his-EGFP B。值得注意的是,为确保目的基因与EGFP基因融合表达后,融合表达产物各组成部分能够保持原有的生物活性,我们运用LINKER程序在EGFP基因的5'端设计了一段编码八肽的连接DNA序列。将一段含有人白细胞介素2（IL-2, human interleukin 2）信号肽编码序列的基因亚克隆进pcDNA6/myc-his-EGFP B的多克隆位点中,使之与EGFP、myc抗原和6×His融合表达,构建成质粒pMHES。用pcDNA6/myc-his-EGFP B和pMHES转染2.2.15细胞,48 h后成功观察到绿色荧光;用pcDNA6/myc-his-EGFP B尾静脉注射Balb/c小鼠,8 h后在小鼠肝脏冰冻切片中同样观察到绿色荧光。用同源建模软件Modeller8V2模拟IL-2与EGFP、myc抗原和6×His融合表达产物的三维结构,结果表明：IL-2、EGFP、myc和6×His各部分互不干扰,连接八肽具有一定的柔性。以上结果表明pcDNA6/myc-his-EGFP B可望作为外源基因在哺乳动物细胞中表达研究和基因治疗的新型载体。     

抗人内皮抑素单克隆抗体杂交瘤细胞的制备及筛选

用亲和层析纯化的酵母表达重组人内皮抑素为抗原,经皮下多点注射免疫Balb/c小鼠,鼠抗血清效价达到1：10000,选免疫效果最好的小鼠,取其脾细胞用PEG法与同系骨髓瘤细胞（SP2／0）融合,通过间接ELISA法对杂交瘤细胞进行筛选,对阳性孔进行有限稀稀,经3次亚克隆获得4株阳性杂交瘤细胞。     

注射突变p53基因CRISPR/Cas9质粒和肝癌细胞建立肝癌小鼠模型

目的 采用尾静脉注射突变p53基因CRISPR/Cas9质粒和H22细胞建立肝癌模型.方法 将健康雄性BALB/c小鼠随机空白组(生理盐水)、质粒组(质粒)、对照组(H22细胞+盐水)、实验组(H22细胞+质粒),每组25只.尾静脉注射建立肝癌模型.分别在注射后的2、3、4、5周中取材,眼眶采血检测小鼠血清转氨酶(AL...     

尾静脉注射和鼻腔接种禽流感H5N1亚型病毒对血细胞的影响

[目的]Balb/c小鼠通过尾静脉注射和鼻腔接种禽流感H5N1亚型病毒造疾病模型,观察其血细胞变化。[方法]以禽流感H5N1亚型病毒通过静脉和鼻腔接种Balb/c小鼠,分别在0~7天和0~11天取血进行血细胞计数和分类,同时对于静脉接种方法进行了0~8小时的短时间监控。[结果]静脉接种途径在接种病毒后2小时就能显著的降低小鼠的白细胞总数、粒细胞及淋巴细胞数,白细胞总数及淋巴细胞数在第3天、粒细胞数在第2天就恢复正常而后均显著升高;而鼻腔接种仅在1~3天淋巴细胞有所降低,而后恢复正常;1~6天白细胞总数及粒细胞数显著升高,而后恢复正常。[结论]从血细胞变化而言,静脉接种相比鼻腔接种方法要好。     

绿色荧光裸鼠的建立和验证

目的建立系统性表达绿色荧光蛋白的裸鼠,接种人源肺癌细胞验证该模型是否具有免疫缺陷性,并观察双色荧光的成像效果。方法利用系统性表达绿色荧光蛋白的C57BL/6J小鼠与BALB/C裸小鼠多代杂交和互交,建立稳定表达绿色荧光蛋白的裸鼠。大体解剖观察胸腺生长情况,整体和器官荧光成像验证绿色荧光蛋白的表达情况。以2×106/只的剂量对其皮下腋下接种表达红色荧光蛋白的人类A549肺癌细胞（RFP-A549）,通过观测肿瘤生长来验证模型的免疫缺陷性。同时,利用红色荧光标记的肿瘤和绿色宿主鼠,对双色的整体成像效果进行观测。结果构建出系统性表达绿色荧光蛋白的裸鼠,大体解剖可见胸腺缺失。在激发光的激发下,绿色荧光裸鼠全身发出清晰的绿色荧光,脑、心脏、肺脏、肝脏、肾脏,肠胃及胰腺等主要器官可见明显绿色荧光。接种RFP-A549细胞后,成瘤率达到100%,整体动物荧光成像表现出清晰的双色。结论本研究构建出的绿色荧光裸鼠,动物整体可以清晰地表达绿色荧光并具有免疫缺陷性     

Lentivirus vector-mediated hematopoietic stem cell gene transfer of common gamma-chain cytokine receptor in rhesus macaques

Nonhuman primate model systems of autologous CD34+ cell transplant are the most effective means to assess the safety and capabilities of lentivirus vectors. Toward this end, we tested the efficiency of marking, gene expression, and transplant of bone marrow and peripheral blood CD34+ cells using a self-inactivating lentivirus vector (CS-Rh-MLV-E) bearing an internal murine leukemia virus long terminal repeat derived from a murine retrovirus adapted to replicate in rhesus macaques. In vitro cytokine stimulation was not required to achieve efficient transduction of CD34+ cells resulting in marking and gene expression of the reporter gene encoding enhanced green fluorescent protein (EGFP) following transplant of the CD34+ cells. Monkeys transplanted with mobilized peripheral blood CD34+ cells resulted in EGFP expression in 1 to 10% of multilineage peripheral blood cells, including red blood cells and platelets, stable for 15 months to date. The relative level of gene expression utilizing this vector is 2- to 10-fold greater than that utilizing a non-self-inactivating lentivirus vector bearing the cytomegalovirus immediate-early promoter. In contrast, in animals transplanted with autologous bone marrow CD34+ cells, multilineage EGFP expression was evident initially but diminished over time. We further tested our lentivirus vector system by demonstrating gene transfer of the human common gamma-chain cytokine receptor gene (gamma(c)), deficient in X-linked SCID patients and recently successfully used to treat disease. Marking was 0.42 and.001 HIV-1 vector DNA copy per 100 cells in two animals. To date, all EGFP- and gamma(c)-transplanted animals are healthy. This system may prove useful for expression of therapeutic genes in human hematopoietic cells.     

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8+ T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40+ lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40- lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8+ T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.     

Comparison between the in vitro activities of in vivo-induced hapten-specific suppressor cells and supernatants of a hapten-specific suppressor hybridoma

A trinitrophenyl (TNP)-specific suppressor hybridoma was obtained by fusing hapten-binding spleen cells (SC) of BALB/c mice 1 week after intravenous (iv) injection of TNP-modified syngeneic lymphocytes with the AKR lymphoma BW5147. The suppressive activity of supernatants from one clone (TNP-44) was compared with that of in vivo-induced TNP-specific suppressor cells. Both the TNP-specific suppressor cells (TsTNP) and the TNP-44 were hapten binding and hapten specific. They suppressed the functional activity of TNP-haptenized T as well as B cells. TNP-44 supernatant also inhibited the proliferation of TNP-modified cells. Using native target cells, both TNP-44 supernatant and the in vivo-induced suppressor cells suppressed the anti-TNP B-cell response to TNP-bound T-dependent soluble or cellular antigens, but not to TNP-lipopolysaccharide (LPS). Furthermore, the function of TNP-specific helper T cells (THTNP) was impaired in the presence of TSTNP or supernatant from TNP-44. From these observations it was concluded that both the TSTNP and a TNP-specific factor derived from a suppressor hybridoma function via an antigen bridge at the TH or at the TH-dependent B-cell subset.     

High volume hydrodynamic injection of plasmid DNA via the hepatic artery results in a high level of gene expression in rat hepatocellular carcinoma induced by diethylnitrosamine

BACKGROUND: Hydrodynamic injection of naked plasmid DNA (pDNA) via the tail vein is a safe and effective method of gene transfer to the liver. However, successful gene transfer has yet to be shown for hepatocellular carcinoma (HCC); therefore, we investigated the feasibility and efficacy of hydrodynamic injection via the tail vein and hepatic artery in a diethylnitrosamine (DEN)-induced HCC model in rats. METHODS: HCC was induced in Sprague-Dawley rats by 100 ppm DEN in drinking water. pCMV-SPORT-beta-galactosidase (beta-gal, 400 microg) was injected (i) via the tail vein in a volume of 0.1 ml/g in 30 s or (ii) via the hepatic artery in a volume of 5 or 10 ml at 1 ml/s, either with or without temporary occlusion of the inferior vena cava (IVC) and portal vein (PV). The liver was harvested 24 h after administration, and beta-gal expression was evaluated with X-gal staining and measurement of enzymatic activity in tissue homogenates. RESULTS: Hydrodynamic injection via the tail vein achieved transgene expression only in non-cancerous tissue (tumor: 0.16 +/- 0.04%, non-tumor: 5.07 +/- 1.66%). Hydrodynamic injection via the hepatic artery was tolerated, but failed to produce efficient transgene expression in tumor and non-tumor cells. On the other hand, concomitant use of temporary IVC/PV occlusion with hydrodynamic injection via the hepatic artery dramatically increased transgene expression in cancer cells, but tumor-selective gene transfer was not achieved with this procedure (tumor: 7.38 +/- 3.66%, non-tumor: 7.77 +/- 1.06%). CONCLUSIONS: High-volume hydrodynamic injection of a pDNA solution via the hepatic artery with IVC/PV occlusion achieved a high level of gene expression in a HCC rat model. This gene transfer technique may have potential in clinical gene therapy for HCC.     

Long-term expression of the human glucocerebrosidase gene in vivo after transplantation of bone-marrow-derived cells transformed with a lentivirus vector

BACKGROUND: Gaucher disease is a lysosomal storage disorder resulting from a deficiency of glucocerebrosidase (GC). Recently, lentivirus vectors have been developed for efficient gene transfer into hematopoietic stem cells (HSCs). A recombinant lentivirus vector was used to evaluate the transduction of the human GC gene into murine bone-marrow-derived HSCs and its expression in their progeny. METHODS: Murine HSCs were transduced with lentivirus vector (lenti-EF-GC; MOI = 10-100). We transplanted female wild-type C57BL/6J mice with genetically modified male HSCs via the tail vein. RESULTS: We show that intravenous transplantation of transduced HSCs has therapeutic potential. Enzyme activity was increased two- to three-fold in various tissues, especially in the hematopoietic system. Numerous transplanted HSCs survived for 6 months and were shown by PCR to contain the provirus genes; the Y chromosome was identified by FISH analysis in the cells of female mouse recipients. CONCLUSIONS: The recombinant lentiviral vector transduces HSCs that are capable of long-term gene expression in vivo. This approach is potentially useful for the treatment of patents with Gaucher disease and other lysosomal storage disorders.     

[F-18]-Fluoro-2-deoxy-<Emphasis Type="SmallCaps">d</Emphasis>-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model

[F-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) is a non-invasive imaging technique which has recently been validated for the assessment of therapy response in patients with aggressive non-Hodgkin’s lymphoma. Our objective was to determine its value for the evaluation of immunotherapy efficacy in immunocompetent Balb/c mice injected with the A20 syngeneic B lymphoma cell line. The high level of in vitro FDG uptake by A20 cells validated the model for further imaging studies. When injected intravenously, the tumour developed as nodular lesions mostly in liver and spleen, thus mimicking the natural course of an aggressive human lymphoma. FDG-PET provided three-dimensionnal images of tumour extension including non-palpable lesions, in good correlation with ex vivo macroscopic examination. When mice were pre-immunized with an A20 cell lysate in adjuvant before tumour challenge, their significantly longer survival, compared to control mice, were associated with a lower incidence of lymphoma visualized by PET at different time points. Estimation of tumour growth and metabolism using the calculated tumour volumes and maximum standardized uptake values, respectively, also demonstrated delayed lymphoma development and lower activity in the vaccinated mice. Thus, FDG-PET is a sensitive tool relevant for early detection and follow-up of internal tumours, allowing discrimination between treated and non-treated small animal cohorts without invasive intervention. C. Chaise and E. Itti contributed equally to the work.     

Comparison of the lateral tail vein and the retro-orbital venous sinus as routes of intravenous drug delivery in a transgenic mouse model

In mice, intravenous injections are commonly administered in the lateral tail vein. This technique is sometimes difficult to carry out and may cause stress to mice. Though injection through the retro-orbital venous sinus can provide certain advantages over lateral tail vein injection, this method is poorly defined and infrequently used. To compare the efficacy of these two routes of drug delivery, the authors injected MAFIA transgenic mice with the depletion agent AP20187, which selectively induces apoptosis in macrophages. Each mouse received five consecutive daily injections through either the lateral tail vein or the retro-orbital venous sinus. The authors then compared macrophage depletion in different tissues (lung, spleen, bone marrow and peritoneal exudate cells). Both routes of injection were similarly effective. A separate experiment using BALB/c mice indicated that retro-orbital venous sinus injection was the less stressful of the two methods.     

抑制小鼠乳腺肿瘤转移 microRNA 的筛选

目的：鉴定25种microRNA的功能及其在乳腺癌中发挥的作用,以筛选新的抑制乳腺癌转移的microRNA分子。方法利用脂质体2000将25种鼠源microRNA表达载体转染至4TO7细胞,经G418筛选结合流式细胞仪分选获绿色荧光细胞得稳定表达鼠源microRNA 的细胞株。将细胞2＆#215;105个/只尾静脉注射接种于BALB/C小鼠,14 d后解剖分离肺组织,统计小鼠肺组织结节数目。结果和接种阴性对照细胞小鼠相比,接种mir-449a稳转细胞的小鼠肿瘤肺转移减少。而接种 mir-1935稳转细胞的小鼠肿瘤肺转移增多。其它23种microRNA稳转细胞接种小鼠肿瘤肺转移既不增加也不减少。结论从25种鼠源microRNA中筛选到2种与乳腺癌肿瘤转移相关的microRNA：mir-449a抑制乳腺癌细胞肺转移,mir-1935则促进癌细胞肺转移。